NYSE:IQV IQVIA (IQV) Stock Price, News & Analysis $243.07 -5.07 (-2.04%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$241.95▼$249.4450-Day Range$206.65▼$251.5552-Week Range$167.42▼$261.73Volume919,808 shsAverage Volume1.06 million shsMarket Capitalization$44.29 billionP/E Ratio33.21Dividend YieldN/APrice Target$266.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get IQVIA alerts: Email Address IQVIA MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside9.7% Upside$266.67 Price TargetShort InterestHealthy1.82% of Float Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment0.59Based on 23 Articles This WeekInsider TradingSelling Shares$320,229 Sold Last QuarterProj. Earnings Growth11.52%From $10.24 to $11.42 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.38 out of 5 starsMedical Sector106th out of 910 stocksCommercial Physical Research Industry4th out of 11 stocks 2.4 Analyst's Opinion Consensus RatingIQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageIQVIA has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IQVIA's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.82% of the float of IQVIA has been sold short.Short Interest Ratio / Days to CoverIQVIA has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IQVIA has recently increased by 13.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIQVIA does not currently pay a dividend.Dividend GrowthIQVIA does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIQVIA has received a 71.38% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pharmacovigilance services", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for IQVIA is -0.69. Previous Next 2.5 News and Social Media Coverage News SentimentIQVIA has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for IQVIA this week, compared to 10 articles on an average week.Search InterestOnly 4 people have searched for IQV on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows3 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IQVIA insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $320,229.00 in company stock.Percentage Held by InsidersOnly 1.60% of the stock of IQVIA is held by insiders.Percentage Held by Institutions89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IQVIA's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for IQVIA are expected to grow by 11.52% in the coming year, from $10.24 to $11.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IQVIA is 33.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.08.Price to Earnings Ratio vs. SectorThe P/E ratio of IQVIA is 33.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.96.Price to Earnings Growth RatioIQVIA has a PEG Ratio of 2.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIQVIA has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IQVIA's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About IQVIA Stock (NYSE:IQV)IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.Read More IQV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IQV Stock News HeadlinesAugust 30, 2024 | insidertrades.comEric Sherbet Sells 1,300 Shares of IQVIA Holdings Inc. (NYSE:IQV) StockSeptember 6 at 5:53 PM | markets.businessinsider.comBuy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription GrowthSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 6 at 5:01 AM | americanbankingnews.comIQVIA (NYSE:IQV) Upgraded to "Buy" at StockNews.comSeptember 5 at 5:29 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and BioMarin Pharmaceutical (BMRN)September 5 at 12:27 PM | msn.comRBC Capital Initiates Coverage of IQVIA Holdings (IQV) with Outperform RecommendationSeptember 5 at 7:27 AM | msn.comContract Research Giant IQVIA's Data Assets Are Biggest Differentiator, Provides Best Exposure To AI And Data Opportunities: AnalystSeptember 5 at 4:19 AM | americanbankingnews.comRoyal Bank of Canada Begins Coverage on IQVIA (NYSE:IQV)September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 4 at 9:00 AM | prnewswire.comSignant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiativeSeptember 3, 2024 | msn.comNorth Hills Innovation District lands first pharmaceutical tenant in ParexelSeptember 2, 2024 | msn.comAurobindo Pharma to focus on growth trajectory, R&D investment and capacity expansionSeptember 2, 2024 | msn.comMankind Pharma announces entry into topical analgesic market, launches Nimulid StrongSeptember 1, 2024 | americanbankingnews.comIQVIA Holdings Inc. (NYSE:IQV) Insider Eric Sherbet Sells 1,300 SharesSeptember 1, 2024 | americanbankingnews.comAnalysts Set IQVIA Holdings Inc. (NYSE:IQV) PT at $265.67August 30, 2024 | finance.yahoo.comIs Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?August 29, 2024 | msn.comUSFDA gives nod to Lupin’s generic formulation for eye disorder treatmentAugust 29, 2024 | americanbankingnews.comIQVIA (NYSE:IQV) Rating Lowered to Hold at StockNews.comSee More Headlines Receive IQV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/22/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNYSE:IQV CUSIPN/A CIK1478242 Webwww.iqvia.com Phone(919) 998-2000FaxN/AEmployees87,000Year Founded2016Price Target and Rating Average Stock Price Target$266.67 High Stock Price Target$300.00 Low Stock Price Target$220.00 Potential Upside/Downside+9.7%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$7.32 Trailing P/E Ratio33.21 Forward P/E Ratio23.74 P/E Growth2.37Net Income$1.36 billion Net Margins9.39% Pretax Margin9.88% Return on Equity28.59% Return on Assets6.76% Debt Debt-to-Equity Ratio1.80 Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$15.16 billion Price / Sales2.92 Cash Flow$15.21 per share Price / Cash Flow15.98 Book Value$33.49 per share Price / Book7.26Miscellaneous Outstanding Shares182,200,000Free Float179,285,000Market Cap$44.29 billion OptionableOptionable Beta1.49 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Ari Bousbib (Age 63)CEO & Chairman Comp: $7.15MMr. Ronald E. Bruehlman (Age 63)Executive VP & CFO Comp: $2.14MMr. Eric M. Sherbet (Age 60)Executive VP, General Counsel & Secretary Comp: $1.37MMr. W. Richard Staub III (Age 61)President of Research & Development Solutions Comp: $886.44kMr. Kevin C. Knightly (Age 63)President of Corporate Strategy & Enterprise Networks Comp: $1.24MMs. Keriann Cherofsky (Age 39)Senior VP, Corporate Controller & Chief Accounting Officer Mr. Jim BerkshireExecutive Vice President of Global Technology & OperationsDr. Jeffrey A. Spaeder M.D.Senior VP, Global Chief Medical & Scientific OfficerKerri JosephSVP of Investment Relation & TreasuryMs. Trudy SteinChief Human Resources Officer & Executive VPMore ExecutivesKey CompetitorsS&P GlobalNYSE:SPGIUber TechnologiesNYSE:UBERMercadoLibreNASDAQ:MELIRelxNYSE:RELXPayPalNASDAQ:PYPLView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 3,419 shares on 9/5/2024Ownership: 0.002%Brown Financial AdvisorsBought 3,036 shares on 8/30/2024Ownership: 0.002%Dana Investment Advisors Inc.Bought 6,019 shares on 8/27/2024Ownership: 0.048%Eric SherbetSold 1,300 sharesTotal: $320,229.00 ($246.33/share)Teachers Retirement System of The State of KentuckySold 403 shares on 8/26/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions Should I Buy IQVIA Stock? IQV Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.: IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry globally. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, providing diversified revenue streams. IQVIA has a strong track record of innovation and technological advancements in the healthcare sector, positioning itself as a leader in the industry. The current stock price of IQV is showing consistent growth and stability, indicating a positive outlook for potential returns on investment. Recent developments in IQVIA's partnerships and acquisitions have expanded its market reach and capabilities, enhancing its competitive edge. Cons Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons: While IQVIA has a strong presence in the healthcare industry, it also faces intense competition from other major players, which could impact its market share and profitability. The company's reliance on regulatory approvals and changes in healthcare policies could introduce uncertainties and risks to its operations and financial performance. IQVIA's business model is subject to fluctuations in demand for its services, which may be influenced by economic conditions and industry trends. Investing in IQVIA Holdings Inc. requires a thorough understanding of the healthcare and life sciences sectors, as well as the ability to assess and manage risks associated with these industries. While IQVIA has shown resilience and adaptability in the face of challenges, investors should consider the potential impact of external factors on the company's growth prospects. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 20, 2024. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com. IQV Stock Analysis - Frequently Asked Questions How have IQV shares performed this year? IQVIA's stock was trading at $231.38 on January 1st, 2024. Since then, IQV shares have increased by 5.1% and is now trading at $243.07. View the best growth stocks for 2024 here. How were IQVIA's earnings last quarter? IQVIA Holdings Inc. (NYSE:IQV) issued its quarterly earnings data on Monday, July, 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.57 by $0.07. IQVIA's quarterly revenue was up 2.3% on a year-over-year basis. Read the conference call transcript. What is Ari Bousbib's approval rating as IQVIA's CEO? 1,545 employees have rated IQVIA Chief Executive Officer Ari Bousbib on Glassdoor.com. Ari Bousbib has an approval rating of 84% among the company's employees. Does IQVIA have any subsidiaries? IQVIA subsidiaries include Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and more. Who are IQVIA's major shareholders? IQVIA's top institutional shareholders include Canada Pension Plan Investment Board (1.87%), Farallon Capital Management LLC (1.60%), Longview Partners Guernsey LTD (1.22%) and Impax Asset Management Group plc (0.90%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, Constantinos Panagos, Kevin C Knightly, John G Danhakl and John Connaughton. View institutional ownership trends. How do I buy shares of IQVIA? Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IQVIA own? Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), NVIDIA (NVDA), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG) and Alibaba Group (BABA). This page (NYSE:IQV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IQVIA Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IQVIA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
